# PACE-LUNG: HCP commentary report

> 76 verified statements (14 from clinicians verified by NPI or staff page) from 16 commentary sources · 8 findings · updated Oct 28, 2026

## Report

- Trial: Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
- NCT ID: NCT05281406
- Registry: https://clinicaltrials.gov/study/NCT05281406
- Sponsor: Goethe University
- Phase: Phase 2
- Status: Recruiting
- Drugs: osimertinib, pemetrexed, cisplatin, carboplatin
- Version: v1.0.0, edition 1
- Accepted: 2026-10-28
- Last checked: 2026-10-28
- Release hash: 2337dba15a23cd206a1fd5268da634be1b10806155936482a141e7bb0ce01dc8

## Counts

- HCP commentary sources screened: 30
- Sources cited by verified statements: 17
- Verified statements: 76
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 14
- Findings: 8
- People found in screened sources: 11
- Voices cited: 11
- Cited voices identity-verified: 10

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

PACE-LUNG asks whether adding chemotherapy when tumor DNA persists in blood during first-line osimertinib improves outcomes in advanced EGFR-mutant NSCLC. Clinicians in the sources reviewed for this edition express interest in selective escalation while leaving comparative benefit unsettled. Feasibility attracts interest, while assessment timing and molecular characterization draw scrutiny. Patient selection remains open. These sources place the trial’s main results at ESMO 2026.

## Open Medical Affairs question

What evidence would justify delaying or omitting upfront combination treatment, and which ctDNA time point and subgroup would support that choice?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Prognostic information is not automatically a treatment-selection rule
- F2. Chemotherapy sparing remains a question, with stronger and more cautious interpretations reported
- F3. Feasibility and favorable historical comparisons attracted interest, without settling comparative benefit
- F4. The three-week trigger and molecular characterization are specific unresolved selection questions
- F5. An individual early decline supported continuing Tagrisso without chemotherapy, with explicitly tentative expectations
- F6. Incidental BRCA2 prompted treatment questions, but not an immediate PARP-inhibitor addition
- F7. Blood-based testing was valued for access and reduced procedure burden, conditional on adequacy and reliability
- F8. Favorable tolerability coexisted with monitoring anxiety, imaging uncertainty and an unproven adjunct rationale

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 6 | 4 | 4 | 3 | none recorded | 3 |
| F2 | 4 | 5 | 5 | 2 | none recorded | 3 |
| F3 | 7 | 7 | 7 | 5 | recorded | 3 |
| F4 | 10 | 8 | 8 | 5 | none recorded | 4 |
| F5 | 9 | 9 | 1 | 0 | none recorded | 4 |
| F6 | 11 | 9 | 1 | 0 | none recorded | 3 |
| F7 | 17 | 15 | 1 | 0 | none recorded | 3 |
| F8 | 12 | 11 | 1 | 0 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 6 | 0 | 0 | 0 | 0 | 9 | 7 | 4 posts and articles | yes |
| F2 | 1 | 3 | 0 | 0 | 0 | 5 | 3 | 5 posts and articles | yes |
| F3 | 2 | 0 | 0 | 2 | 3 | 10 | 2 | 7 posts and articles | yes |
| F4 | 2 | 2 | 2 | 1 | 3 | 11 | 2 | 5 posts and articles, 2 podcasts and video, 1 registry | yes |
| F5 | 7 | 0 | 1 | 0 | 1 | 10 | 2 | 1 podcast or video | yes |
| F6 | 2 | 3 | 1 | 0 | 5 | 11 | 0 | 1 podcast or video | yes |
| F7 | 8 | 0 | 3 | 1 | 5 | 17 | 3 | 1 podcast or video | yes |
| F8 | 3 | 1 | 4 | 1 | 3 | 12 | 1 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Progression Free Survival (PFS1): F3 (5 shared claims), F4 (1 shared claims)
- Secondary endpoints: F3 (2 shared claims)
- Population and setting: F4 (1 shared claims), F7 (3 shared claims)
- The comparison: F1 (4 shared claims), F2 (1 shared claims), F3 (3 shared claims), F4 (2 shared claims)
- Safety and tolerability: F6 (1 shared claims), F8 (3 shared claims)
- Design and conduct: F3 (4 shared claims), F4 (5 shared claims), F7 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F4. The three-week trigger and molecular characterization are specific unresolved selection questions

Posts on X asked about the timing of the ctDNA assessment used to select chemotherapy escalation and about co-mutations in patients selected for escalation.

The clinical roles of the authors asking these questions are not stated in the sources reviewed for this edition.

Source: X thread, 2026-10-24.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 76 | Paid |
| Trial aspects mapped | 13 | Free |
| Sources with links | 17 | Counts free |
| Speaker attribution for cited voices | 11 | Paid |

## Trial aspects

13 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression Free Survival (PFS1) | discussed | 5 | 6 |
| Secondary endpoints | discussed | 2 | 3 |
| Population and setting | discussed | 4 | 2 |
| The comparison | discussed | 11 | 9 |
| Safety and tolerability | discussed | 4 | 1 |
| Design and conduct | discussed | 10 | 7 |
| Prognostic versus predictive value and chemotherapy sparing | discussed | 11 | 7 |
| Assessment timing, later clearance and co-mutations | discussed | 5 | 5 |
| Individual no-chemotherapy pathway and expectations of durability | discussed | 9 | 1 |
| Incidental BRCA2, add-on treatment ideas and genetics referral | discussed | 11 | 1 |
| Baseline assay detectability and conditional preference for noninvasive sampling | discussed | 12 | 1 |
| Monitoring burden, pleurodesis-related imaging uncertainty and adjunct use | discussed | 9 | 1 |
| Research interest and molecular-subtype reassurance | discussed | 6 | 3 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 27 | 13 |
| YouTube | 2 | 2 |
| Podcasts | 1 | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2022-03-16 to 2026-10-28
- Cited window: 2023-05-29 to 2026-10-28
- Retrieved: 2026-10-28

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
- Registry: NCT05281406 (https://clinicaltrials.gov/study/NCT05281406)
- Study IDs: PACE LUNG
- Sponsor: Goethe University
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Recruiting
- Enrollment: 50 (estimated)
- Start: 2021-11-12 (actual)
- Primary completion: 2025-11 (estimated)
- Primary endpoint: Progression Free Survival (PFS1) (2 years)
- Intervention: Osimertinib (drug)
- Intervention: Pemetrexed (drug)
- Intervention: Cisplatin (drug)
- Intervention: Carboplatin (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 45 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not a representative survey of HCPs. Repeated posts and relays of the same discussion cannot be counted as independent agreement.
- No full protocol or exact-trial results publication was available. Registry statements describe methods and hypotheses; reported outcomes come from commentary about presentations.
- Discussions that do not name PACE-LUNG, or use different spellings, may be absent. Some relevant passages were not fully assessed, so the report is not a complete account of public discussion.
- The podcast and preview speech cannot be assigned to named individuals. The podcast does not establish that its personal treatment accounts are HCP recommendations.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Reported PFS and OS estimates have different or incompletely specified time origins. Historical comparisons and presentation relays cannot establish comparative treatment benefit.
- Baseline-undetectable patients and patients achieving clearance after starting treatment are different groups; favorable prognosis does not by itself establish that chemotherapy can safely be omitted.
- Personal accounts do not provide aggregate adverse-event, comparative safety or trial quality-of-life results. The hyperthermia rationale is not demonstrated clinical benefit.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-28: current edition

Last checked for new commentary 2026-10-28. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (76 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (10 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/pace-lung-nct05281406
- Agents: POST https://www.erudio.com/api/orders with {"report": "pace-lung-nct05281406", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=pace-lung-05281406

## Cite

Erudio Health. PACE-LUNG (NCT05281406): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 28, 2026. https://www.erudio.com/reports/pace-lung-nct05281406

## Machine access

- JSON: https://www.erudio.com/reports/pace-lung-nct05281406.json
- Markdown: https://www.erudio.com/reports/pace-lung-nct05281406.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "pace-lung-05281406"}`